Allarity Therapeutics, Inc.

Develops personalized cancer drugs using a diagnostic platform to predict patient response.

ALLR | US

Overview

Corporate Details

ISIN(s):: US0167445008
LEI:
Country:: United States of America
Address:: 24 SCHOOL ST., 2ND FLOOR, 2108 BOSTON
Website:: https://allarity.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing personalized cancer treatments. The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes tumor biology to predict a patient's response to specific therapies. This approach aims to refine patient selection and improve clinical outcomes for its pipeline of in-licensed oncology therapeutics. Allarity's lead clinical program is stenoparib, an orally available, dual-action small molecule inhibitor being advanced for patients with advanced recurrent ovarian cancer. The company's mission is to enhance patient outcomes through data-driven decision-making and personalized cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allarity Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allarity Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allarity Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Oric Pharmaceuticals, Inc. Developing therapies to overcome resistance in lung and prostate cancer.	United States of America	ORIC
Orion Oyj Develops and manufactures human/vet pharma, APIs, and generics for global markets.	Finland	ORNAV
Oruka Therapeutics, Inc. Develops long-acting antibody therapies for chronic inflammatory and skin diseases.	United States of America	ORKA
Orum Therapeutics, Inc. Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.	South Korea	475830
OSR Holdings, Inc. Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.	United States of America	OSRH
OS Therapies Inc Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.	United States of America	OSTX
Otsuka Holdings Co., Ltd. Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.	Japan	4578
Outlook Therapeutics, Inc. Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.	United States of America	OTLK
Ovid Therapeutics Inc. Developing targeted small molecule therapies for rare neurological diseases and epilepsies.	United States of America	OVID
Ovoca Bio Plc Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).	Ireland	OVXA